Human Genome Epidemiology Literature Finder
Records 1 - 6 (of 6 Records) |
Query Trace: Adenocarcinoma and STAT3[original query] |
---|
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer biology & therapy 2011 Jul 12 (1): 1. Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, Bang YJ, Kim WH, Tretiakova M, Vokes E, Frank DA, Kinder HL, Huet H, Salgia R |
Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. Molecular diagnosis & therapy 2011 Dec 15 (6): 347-52. Jiang Richeng, Jin Ziliang, Liu Zhujun, Sun Leina, Wang Liuchun, Li K |
EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma. Medical oncology (Northwood, London, England) 2017 Sep 34 (10): 175. Clay Timothy D, Russell Prudence A, Do Hongdo, Sundararajan Vijaya, Conron Matthew, Wright Gavin M, Solomon Benjamin, Dobrovic Alexander, McLachlan Sue-Anne, Moore Melissa |
Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2020 5 29 (7): 1501-1508. Zhu Jingjing, Shu Xiang, Guo Xingyi, Liu Duo, Bao Jiandong, Milne Roger L, Giles Graham G, Wu Chong, Du Mengmeng, White Emily, Risch Harvey A, Malats Nuria, Duell Eric J, Goodman Phyllis J, Li Donghui, Bracci Paige, Katzke Verena, Neale Rachel E, Gallinger Steven, Van Den Eeden Stephen K, Arslan Alan A, Canzian Federico, Kooperberg Charles, Beane Freeman Laura E, Scelo Ghislaine, Visvanathan Kala, Haiman Christopher A, Le Marchand Loïc, Yu Herbert, Petersen Gloria M, Stolzenberg-Solomon Rachael, Klein Alison P, Cai Qiuyin, Long Jirong, Shu Xiao-Ou, Zheng Wei, Wu La |
Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: a real-world retrospective study. Journal of thoracic disease 2020 11 12 (10): 5324-5335. Lv Chao, Ma Yuanyuan, Feng Qin, Lu Fangliang, Chi Yongkun, Wu Nan, Fang Jian, Yang Y |
EGFR and PDL1: A Match (Not) Made in Heaven-A Real-World Retrospective Analysis of PDL1 Expression in EGFR-Mutated NSCLC. Advances in therapy 2021 2 38 (4): 1791-1800. Batra Ullas, Sharma Mansi, Nathany Shrinidhi, Bansal Abhishek, Pasricha Sunil, Jain Parveen, Mehta Anurag, Singh Harkir |
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 25, 2024
- Content source: